Glioblastoma

Within the studies here, there are a few examples of patients reported with no evidence of disease at the time of publication. Indicating that natural compounds can, for some, radically improve the results of their oncology treatments by helping the drugs effectiveness, but also by reducing side effects that impact oncology.

Chlorogenic acid, easily available from green coffee supplements, is moving towards chinese FDA approval for GBM. Phase I trials have shown quite striking benefits used as a injectable form of chlorogenic acid, but absorption from supplements is high. Chlorogenic acid has clear evidence in lab models for suppressing M2 macrophages- large immune cells – seen to be used by cancer tumors in treatment evasion, increasing growth and even metastasis. Most patient responses were in the lower dose ranges here, probably attainable with premium grade supplements. The mechanisms include immune system modulation, moving from inflammatory to anti-inflammatory state.

Functional foods derived from eggs or oats increase so called anti-secretory factor can reduce the internal fluid pressure in tumors. This pressure fuels GBM growth and metastasis, and is especially a problem in drug resistance with the physical barrier it presents. A pilot in sweden trial recently showed some fascinating outcomes in a small patient group, with half those able to compete the treatment seeing over two years response. The researchers particulary highlight one patient remaining in remission at the trial close. Studies are being extended in GBM and several other cancers. Also food related, ketogenic diets are showing some fascinating results in particular for glioblastoma (see Lifestyle)

In late stage patients that included GBM, moderate to high dose melatonin has shown some remarkable effects, inducing periods of stable disease for some patients. In other cancers up to 1000mg has been safely given, and more trials are called for by these research teams. Also emerging in studies is the supporting use of niacin or nicotinamide during oncology. Pre-clinical evidence clearly showed a striking ability to activate the immune system activity in tumors, and controlled release versions of this common vitamin B3 varient are already in phase I trials. Similar progress with high dose intravenous vitamin C have already been published, and showed remarkable sustained responses in a subgroup of patients lacking so called MGMT promoter methylation markers.

As well as using glucose (glycolysis), GBM is known to upregulate fatty acid metabolism including raised L-carnitine levels. This increases treatment resistance, leading to sharply increased progression rates in some patients. In anti-aging science, urolithin A supplements are reported re-regulating fatty acid uptake. And it can also pass the blood-brain barrier, there are researchers calling for trials in GBM. Another even more established mechanism by which GBM tumors fuel growth is upregulation of so called unfolded protein response. Some fascinating new research shows how inhibiting enzymes involved with this process can stop disease progress in mouse models. Quercetin, perhaps aided by tocotrienols to cross the blood brain barrier (vitamin E), may have inhibiting activity of these enzymes.

Inflammation related iron deficiency is a feature of cancer progression. At the same time, upregulated iron stored as ferritin increases progression rates. Pre-biotic milk protein lactoferrin binds iron in the gut, increasing its absorption. By regulating iron balance, homeostasis, its action may counter some of the dysfunctional iron metabolism. Elevated neutrophil-to-lymphocyte ratios, including a rise during treatment, increase risk levels. Immune balancing effects of astragalus have been reported in advanced lung cancer as improving NLR. Other inflammatory activity measured by c-reactive protein and fibrinogen levels are also reported risk factors that may be countered by curcumin, aged black garlic and more.

The so called Th1/Th2 immune system balance is strongly linked to the progression and to treatment resistance. Molecular iodine solutions are emerging in this area in breast cancer management and seen boosting Th1 anti tumor activity and helping suppress over active Th2 used in resistance. This has improved results in surgery plus chemotherapy and this form of iodine can pass the blood brain barrier. Itmay support increased response immunotherapy which a small group of GBM treatment plans might include (see Supplement Library). For immunotherapy the presence of high sodium levels is now identfied as a key marker for success in other cancers. Also in other cancers, AM treatment programs are substantially more effective that PM/evening sessions

Subscribe to the site for Pathfinder ANALYSIS and helpful GUIDE. Build you personal plan with confidence.

Click the IMAGE to view the library entry

Green Coffee Extract is high in chlorogenic acid and other cancer fighting natural compounds

Almost 2X increased survival in stage IV GBM and 2 patients of 23 beyond 5 years
Half of patients saw over 20 months, a quarter over 30 months
Doses are within reach for high quality supplements for their safety testing

Twenty-three patients were analyzed for their response to CGA [chlorogenic acid]. The disease control rate [stable disease] after 4-week injections (the first cycle) was 52.1% (SD, 12) . Of the 9 patients in the 3 mg/kg cohort, the brain tumor lesions in 3 patients shrank but did not reach the criteria for partial response at the end of first treatment cycle. Six patients (6 out 9, 67%) achieved SD in this cohort

Oat and egg based functional foods are entering early stage clinical trials for several cancers

A 55% improved survival with functional food delivered anti-secretory factor
Two thirds of those able to compete treatment show survival beyond 2 years
One of these patents was classed as disease free and beyond 2 years after the trial closed

At the latest follow-up, three (38%) patients remained alive, one of whom was free from recurrence. Figure 2 illustrates this latter patient. Survival data are reported in Table 1. Median OS was 23.0 months. Median PFS was 10.2 months…To make a meaningful comparison of survival, we selected an age and treatment matched retrospective cohort. Compared to this cohort, the treated patients displayed higher median OS (23.0 months versus 14.8 months) and PFS (10.2 months versus 9.4 months) compared to controls, but this was not statistically significant [now moving to a larger t...

Melatonin trials have shown longer survival rates, even in late stages, and improved side effects

3/5 late stage glioblastoma patients experienced notable response
Of these, one patient reported as over 10 months stable after melatonin
A patient case here with rare astrocytoma also reported 10 mths+ stable

A preliminary study with a very high dose of MLT, consisting of 1000 mg/once day in the evening, was carried out in untreatable cancer patients, who failed to respond to the conventional anticancer therapies, and for whom the only available treatment was the palliative therapy. The treatment was well tolerated, and a disease control was achieved in 54% patients. These preliminary results would justify further clinical studies to generate a new interpretation of cancer control

Vitamin D3 and its immune system health actions are key, higher doses being trialed in oncology

Patient data on use of supplements shows vitamin D3 was beneficial
An adjusted overall surival increase reported as 26%
Aligns with large scale patient data in multiple cancer types

Vitamin D supplementation could potentially increase survival by mitigating some of the immunosuppressive effects of SOC treatment or by aiding the immune system in preventing the growth of tumor cells… Vitamin D has been reported to improve patient outcomes and to be associated with the occurrence of less aggressive tumors across multiple cancer types.. although, to our knowledge, this is the first report of a survival benefit in GBM. Given the mechanistic support underlying these findings, current results for vitamin D merit further study

Vitamin B3 here in the niacin form is in research for GBM

Compelling pre-clinical response is the basis for ongoing phase I studies
Niacin B3 is able to switch back crucial immune reactions in tumor cells
Findings are verified in both mouse models and patient derived cells

Niacin treatment of mice bearing intracranial BTICs increased macrophage/microglia representation within the tumor, reduced tumor size, and prolonged survival. These therapeutic outcomes were negated in mice depleted of circulating monocytes or harboring interferon-α receptor–deleted BTICs. Combination treatment with temozolomide enhanced niacin-promoted survival. Monocytes from glioblastoma patients had increased interferon-α14 upon niacin exposure and were reactivated to reduce BTIC growth in culture. We highlight niacin, a common vitamin that can be quickly translated into clinical a...

Vitamin C as a high dose drop is rapidly emerging in oncology for several advanced cancers

Pilot study of high dose intravenous vitamin C with oncology treatment
Tendencies to improved overall survival of around 1/3
3 of 11 patients reported with longer sustained period of stable disease

This study reports the first-in-human combination of pharmacologic ascorbate, RT, and TMZ therapy. Data suggest that P-AscH− [intravenous vitamin C] is safe when combined with RT and TMZ, with minimal toxicity relative to standard RT/TMZ therapy. Although not powered to detect changes in effect size, data suggest that P-AscH− may enhance RT/TMZ effectiveness in patients with GBM, improving both PFS and OS, especially in subjects with undetectable MGMT promoter methylation and IDH wild-type status. Results are sufficiently promising to merit a phase II investigation

Urolithin A increases healthy cellular behaviors that may reduce cancers upregulated fatty acid metabolism

GBM tumors dysfunctional fatty acid metabolism increase growth and resistance
Case data shows 2.7X reduced risk in patients with lower activity in this pathway
Other research calls for trials of Urolithin-A in to explore its benefits

It has been previously shown that the OCTN2 substrate LC [L-carnitine] acts as a cytoprotector promoting cellular resistance and survivability..in this study, we demonstrate that OCTN2 expression and tissue LC concentrations are significantly higher in GBM compared with healthy brain. We observed a stepwise increase of OCTN2 expression from low-grade astrocytoma to primary and recurrent GBM. These findings are consistent with those of Bayraktar and colleagues who described a gradual increase in LC levels and some of its acyl derivates from low- to high-grade astrocytomas through to primary ...

Quercetin is one of few natural compounds able to penetrate the blood brain barrier

IRE1 enzymes are closely linked to increased progression and resistance
Anaysis of case data reports clear link between IRE1 activity and response
New lab studies shows quercetin can strongly suppress human IRE1 activity

We found that sensitivity to a UPR inducing prodrug may be hindered not only by constitutively-high levels of activation of the UPR but also by a heightened expression of genes encoding proteins central to IGF-1 signaling. Remarkably, the NR signature was validated in TCGA and found to account for>65% of GBM cases. Therefore, new UPR-based therapies need to take into consideration the role of elevated IRE1α and IGFBPs making it urgent to develop strategies to disable them, thereby decreasing resistance and increasing sensitivity to UPR therapies.

Lactoferrin increases iron balance and reduces anemia rates, countering cancers use of iron

More than double average survival time with higher serum iron
Adjusted risk reduction of 21% reported here aligns with other studies
At the same time, iron deficiency is common and linked with poor prognosis

Whether iron itself may be mediating improved survival or whether it may simply be a prognostic marker of an anti-tumor response requires additional study. Pre-clinical evidence does suggest that iron may directly play a beneficial role with reports of iron promoting anti-tumor immunity, inhibiting the ability of glioblastoma cells to migrate, and promoting ferroptosis of glioblastoma cells… iron may be associated with improved outcomes and may potentially be able to be utilized as a prognostic marker. this study provides additional evidence that iron may be associated with improved o...

Astragalus actions include protecting and balancing immune responses often with clear effects reported

Lower neutrophil-to-lymphocyte ratio, NLR, reduces risks
Both 1 and 2 year overall risk levels reduced more than half
Astragalus has evidence in lung cancer to re-balance NLR levels

The results of our present retrospective cohort analysis intimated that high pretreatment NLR measures were connected with significantly diminished survival durations in R-GBM patients treated with salvage BEVIRI. If confirmed by appropriately designed large-scale research results, NLR might be utilized as a costless, easy to achieve and calculate and reliably reproducible novel biologic factor in the prognostic stratification of the R-GBM patients into two groups with significantly distinct prognoses that may conceivably guide their individualized treatment.

Curcumin has evidence for reducing levels of systemic inflammation used by cancers

Systemic inflammation related progression assessed with 2 biomarkers
C-reactive protein and Fibrinogen levels indicate increased risk
Lower levels of both biomarkers reported risk reduction about a third

In this study, we evaluated the FC score as a prognostic dual biomarker score for GBM patients. We observed significantly decreased overall survival times in patients with an increased FC score (≥1) at the time of GBM diagnosis. An elevated FC score can be measured via determination of the plasma fibrinogen level and the serum CRP level prior to surgery for GBM and was found to be an independent risk factor for shortened survival. Our findings suggest the potential importance of assessing the prognosis of GBM by combining clinicopathological characteristics with initial inflammatory statu...

Support us and get our essential pathfinder GUIDE. Impacts Analysis, Usage and doses, EXAMPLE plan and supporting comments

GUIDE

Pathfinder Element	Risk Reduction Factor	Anti-Metastatic	Reduces Side Effects	Research Study
Oat and Egg functional foods	>50%	Probably	Yes	Link
Ketogenic diet & supplements	>50%		Probably	Link
Green Coffee Extract	>50%	Maybe		Link
Vitamin D3	26 - 50%	Yes	Maybe	Link
Intravenous Vitamin C	26 - 50%
Melatonin	Up to 25%	Maybe	Yes	Link
Astragalus	Indirect - High	Yes	Yes	Link
Lactoferrin	Indirect - High	Probably	Yes	Link
Urolithin A	Indirect - High	Probably	Maybe	Link
Vitamin B3	Indirect - High	Maybe		Link
Quercetin	Indirect - High	Maybe		Link
Curcumin	Indirect - Moderate	Maybe	Maybe	Link

Plan Item	Cancers	Background Details	Trial Doses Under Supervision	References
Antihistamines	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Gastric, Ovarian, Cervical, Pancreatic, Melanoma, Lymphoma, Esophageal, Bladder	Research indicates desloratadine for localized cancers or loratadine for metastatic. There are examples of ebastine or other alternatives in certain cases. Growing research evidence indicates improved oncology responses. Taken between meals. Low histamine before and during treatment is beneficial.	Active use in clinical trials is still in early phase, follow the dose recommendation for instance 5mg daily unless under medical supervision where higher 10mg doses are frequent
Aspirin	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Ovarian, Cervical, Endometrial, Pancreatic, Melanoma, Myeloma, Head and Neck, Bladder, Gallbladder, Non Melanoma Skin, Gastric	Use of low dose 75 or 81mg "baby" aspirin is reported to benefit many cancer types across an average study group, and even all cause mortality. There are some indications of specific "responders" for instance those with existing inflammatory conditions or certain gene expressions. With food.	In a colorectal cancer trial responders were tied to the expression of particular genes (PI3KA). Doses were 160mg	LINK
Astragalus	Breast, TNBC, Lung, Colorectal, Liver, Gastric, Cervical, Endometrial, Pancreatic, Prostate, Kidney, Ovarian, Glioblastoma, Non Hodgkin, Lymphoma, Leukemia, Myeloma, Head and Neck, Bladder, Gallbladder, Thyroid	A typical astraglaus membranaceus supplement may have 50mg of astragaloside IV the main active compound. Its possible with meals can reduce any stomach upset. Use of a standard dose to help immune system balance before treatment.	Here, Astragalus is added to standard oncology in lung cancer Doses are 2-3 tablets of 250mg AMe (Solgar, NJ, USA) minimum for 6 months in this example	LINK
Beta Glucans	TNBC, Lung, Liver, Gastric, Cervical, Pancreatic, Melanoma, Non Hodgkin, Lymphoma, Leukemia	There are many options for mushroom or yeast 1,3/1,6 glucan and branded products include California Gold Immune Defense/Wellmune, AHCC, Biogen/ Yestimun, ImmiFlex, IP6 and many more. A pharma grade product, odetiglucan, is continuing in trials. Take on an empty stomach. Use a standard dose to help balance the immune system before starting treatments.	AHCC is used at 3x1g per day over several months during treatment. Beta glucans are used at 1-2g per day and higher.	LINK
Danshen	Breast, Prostate, Lung, Colorectal, Liver, Leukemia, Myeloma, Bladder	The most common chinese herbal medicine in oncology, also known as red sage. Premium brands such as MCS may recommend 1g twice daily as an ongoing dose. Its possible with meals can reduce any stomach upset. Start a standard dose a couple of weeks before treatment to help balance the immune system.	3 x1g daily between meals , over at least 90 days ideally longer to get maximum benefits according to reported patient outcomes, though even shorter dose period reduced risk	LINK
Green Coffee Extract	Glioblastoma	Supplements vary in terms of their chlorogenic acid content, it can be up to 50%. Quality brand might specify this level under their recommended intake. High dose commercial brands may be over 1000mg total, take before meals.	Analysis across trials reports metabolic health benefits start are higher at >500mg or daily. High chlorogenic acid content supplements eg Svetol have been trialed safely for 12 weeks at 200mg x 5 daily dose. As always, be aware of possible drug interactions	LINK
Red Yeast Rice Or statin	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Gastric, Ovarian, Cervical, Endometrial, Melanoma, Leukemia, Myeloma, Head and Neck, Esophageal	Red yeast rice is equivalent to lovastatin. Doses are essentially on the products, and there are many premium brands with guaranteed level of monokolin k around 3mg. A common theme is findings is those with improved cholesterol are "responders". With meals. Start cholesterol and inflammation reducing statins early.	Trial data is often case studies with multiple statins where lovastatin has average effects. Often atorvastatin and sometimes simvastatin come out on top. Research ususally reports intermediate doses ( 10-20mg) are effective but there are examples indicating higher doses under supervision.	LINK
Turkey Tail	Lung, Colorectal, Kidney, Liver, Gastric	A typical premium supplement such as MCS recommend 700mg twice daily with food. Mushroom based glucans can help balance immune response so start them before your treatment.	Pharma grade turkey tail, e.g PSP/ PSK/ Krestin is typically used at 3x 1g daily during oncology, up to 36 months and more. Trials in breast cancer have also used 3,6 and 9g daily regimes in 6 week periods	LINK
Vitamin D3	Breast, TNBC, Prostate, Lung, Colorectal, Gastric, Ovarian, Pancreatic, Glioblastoma, Melanoma, Non Hodgkin, Lymphoma, Leukemia, Myeloma, Head and Neck, Esophageal, Bladder	High dose commercial formulae can be 10,000IU. Which might be achieved by as little as 10 to 20 minutes in sunshine. Vitamin K2 is advised with D3. Take with some food containing fat. Its important to ramp these up before oncology treatments, and sustain the higher levels over time. Add magnesium for best absorption and metabolism.	The VITAL trial used 2000IU and discussed the potential of higher doses to increase responders especially higher BMI/ body weight. Whilst in prostate cancer there are trials demonstrating at least 10,000IU is required to see activity reducing PSA levels	LINK
Melatonin	Breast, TNBC, Prostate, Lung, Kidney, Liver, Ovarian, Cervical, Endometrial, Pancreatic, Glioblastoma	Commonly used in 10 to 40mg daily range no reported side effects, typically an hour before sleep.	Moderate and high dose trials report no significant side effects even at 1000mg daily	LINK
Citrus Pectin	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Ovarian, Cervical, Endometrial, Pancreatic, Non Hodgkin, Leukemia, Myeloma, Head and Neck, Esophageal, Bladder, Gallbladder, Thyroid, Gastric	Trials use a recommended dose up to 5g x3 daily and no significant side effects. Taken 30 minutes before or 90 minutes after food. Ideally, start PectaClear or similar products at least 4 week before treatment to reduce heavy metals. But sustain zinc with supplementation	Even in children age 5 to 12 the daily regime 3 x 5g was safe and effective for heavy metal chelation	LINK
Soy Isoflavones	Breast, Prostate, TNBC	Often dietary sources, tofu and soy based and no evidence of side effects. Supplements generally with food.	In a clinical trial setting up to 900mg with no issues	LINK
Fermented Wheatgerm	Prostate, Colorectal, Melanoma	Trials are with Avemar brand products with no significant safety concerns reported	Typical dose regimes may be aroung 9g daily over longer time periods for instance 12 months	LINK
Iodine	Breast, TNBC	General usage around 1000mcg or 1mg generally with food	Successful pilot studies in breast cancer use 5mg molecular Iodine daily for the duration of therapy	LINK
Lactoferrin	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Gastric, Ovarian, Cervical, Endometrial, Pancreatic, Glioblastoma, Melanoma, Non Hodgkin, Lymphoma, Leukemia, Myeloma, Head and Neck, Bladder, Esophageal, Gallbladder, Thyroid	200mg typical use daily , eg 10ml liposomal formula ideally 30 minutes before meals or 2 hours after. No side effects of note. Start this immediately to achieve and maintain healthy iron absorption, avoid deficiencies and reduce cancer related ferritin levels.	During oncology doses of up to 3g to 9g daily, even higher, have been used with significant side effects	LINK
Selenium	Breast, Lung, Kidney, Ovarian, Cervical, Endometrial, Pancreatic, Melanoma, Head and Neck	Supplements are 200ug doses and similar amounts from about 3 brazil nuts. Start buildin gup your levels immediately and keep them high during oncology. Selenium toxicity is a consideration for high doses over time, so seek medical advice. Ideally taken with meals.	This trial used 2500 to 4000ug 2x daily for 14 days then once daily in kidney cancer with no dose limiting toxicity	LINK
Vitamin B3	Liver, Gastric, Glioblastoma, Non Hodgkin, Lymphoma, Leukemia, Non Melanoma Skin	Typically 500mg for nicotinamide (niacinamide) form of B3 taken ideally with meals	Do not differ from standard doses, here 500mg twice daily related to skin cancer	LINK
Akkermansia	Breast, TNBC, Prostate, Lung, Kidney, Liver, Ovarian, Cervical, Pancreatic, Non Hodgkin, Lymphoma, Leukemia, Myeloma, Head and Neck, Gastric	Commercial products may be at 10B CFU typically 30 minutes before or 2 hours after food. Ramp up levels with diet and moderate supplementation before treatments, especially immunotherapy.	Under development. Results in oncology indicate this is one of many helpful guy bacteria. careful consideration and particularly following use of antibiotics. Diversity is crucial.	LINK
Berberine	Kidney, Liver, Cervical, Pancreatic, Non Hodgkin, Leukemia, Myeloma, Head and Neck, Esophageal, Gallbladder, Thyroid, Non Melanoma Skin, Melanoma, Bladder	A natural anti-diabetic used frequently at 400mg daily and above, shortly before meals	In metabolic health trials frequentlu use up to 500mg at 3 times daily .	LINK
Curcumin	Colorectal, Liver, Non Hodgkin, Myeloma, Bladder, Gallbladder, Non Melanoma Skin, TNBC, Breast, Prostate, Lung, Kidney, Gastric, Ovarian, Cervical, Endometrial, Glioblastoma, Melanoma, Lymphoma, Leukemia, Head and Neck, Thyroid	Doses from 500mg to 2000mg frequently seen. Piperine fron black pepper improves absorption, highly bioavailable formulae are available. Ideally with a meal containing fat.	Higher doses in trials are frequently 2 of 4 g daily (+40 mg piperine) during oncology for instance here at 3 periods of 30 days	LINK
Quercetin	Glioblastoma, Myeloma	Can be found in a healty diet. Supplements often 500 or 1000mg and can be taken with tocotrienols for enhanced absorption, a form of vitamin E . Some evidence that Quercetin should be pulsed on/off.	Clincial trials have safely used up to 5g daily in adults, and 1 to 4g for rare forms of paediatric anemia	LINK
Urolithin A	Prostate, Lung, Colorectal, Kidney, Gastric, Glioblastoma, Melanoma, Myeloma, Gallbladder, Head and Neck	Typical commercial brands run at 500mg once or twice daily, with or without food, some brands suggest with meals	Trials eg in anti-aging science use the same dose range	LINK
Oat and Egg Functional Food	Breast, TNBC, Prostate, Lung, Colorectal, Kidney, Liver, Cervical, Pancreatic, Glioblastoma, Melanoma, Head and Neck, Gallbladder	Follow supplier guidance on dosage and use. https://shop.lantmannenfunctionalfoods.com/? Lowering tumor fluid pressure helps treatments work, start these before your treatment if possible. Use egg based salovum for short term "pulse" during therapy and oat products for sustained use over longer time periods	This trial in glioblastoma used 16g egg based Salovum four times daily. It discusses lowering that regime in follow on trials.	LINK
Coffee	Breast, Prostate, Colorectal, Liver, Non Melanoma Skin	Most dietary studies use standard 8oz servings as a guide. In many cases the findings are that benfits increase with intake. But in some cases such as prostate cancer there are important details in the PATHFINDER	No, but chlorogenic acid and, separately, green coffee extracts are used at 400mg and up to 2000mg
Flax	TNBC, Ovarian	Crushed flaxseed alone or in foods around 1/4 cup daily	Doses up to 50g daily in clinical trials for various diseases. Here a fairly typical 30g regime in inflammatory liver diseases	LINK
Propolis	Breast	Typical supplements range from 400 to 1000mg	Here 400mg x3 daily help recovery from radiotherapy	LINK
Walnuts	Prostate, Colorectal, Melanoma, Head and Neck	Dietary food item shown even at low useage to be helpful even at a few oz per week	Here, 2oz (56g) daily showed measurable activity in breast cancer	LINK
Mushroom	Prostate	Both dietary sources and many commercial supplements normally taken with food	In this example some patients saw responses between 8 and 14g daily of button mushroom extract	LINK
Zinc	Kidney, Ovarian, Cervical, Endometrial, Head and Neck, Non Melanoma Skin	Commercial supplements vary considerably . Moderate 20mg range generally advised	No
Intravenous HIgh Dose Vitamin C	Pancreatic, Glioblastoma	Commercial supplements vary. A moderate range around 20mg with food is generally accepted as safe.	Same as general guidance
Alpha Ketoglutarate	Melanoma, Kidney, TNBC, Non Hodgkin, Lymphoma	Typical usage is 1000mg daily with or without food, safety is good. Its especially important to ramp up and sustain your levels for maximum immunotherapy responses.	Larger doses of several grams have been safely used in various trials including here in bone disease at 6g daily	LINK
Horse Chestnut (Escin)	Thyroid	Common 300 to 600mg supplements contain 50 to 120mg of active compound, escin taken with food	Escin up to 150mg daily in vascular health. In oncology 0.6 mg/kg/day for 9 days, intravenous injection has been used, high absorption premium supplement would reacj this level	LINK

Treatment consists of surgery, radio and chemotherapy and temozolomide. Beyond this, more recently introduced classes of oncology drugs maybe added primarily to help quality of life.

Your PATHFINDER brings together research that may help maximize the effects of these treatments. The IMPACTS tab summarizes these and can lead to Many more Good days by helping these treatments work, reducing your risk for progression and by easing treatment side effects. You can continue to look for ways to increase the results and reduce possible toxicities;

Be sure to fully read and absorb the PATHFINDER and its Impacts summary
If you have metastatic sites take a look into the corresponding Pathfinder for those too, for inspiration.
Use the Supplement Library Index and filter on “Chemotherapy” and “Targeted drugs” for ideas.
The Foods Library can complement your plan, including anti-metastatic strategies and metabolic health
In the Lifestyle section gathers fascinating evidence for diets and exercise
The PLANS section may have information from what others are doing and have learned

Glioblastoma

Help grow the community